May 26, 2022 6:00pm EDT Immunocore announces upcoming presentations at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting
May 11, 2022 7:00am EDT Immunocore Reports First Quarter 2022 Financial Results and Provides Business Update
Apr 04, 2022 7:00am EDT European Commission Approves KIMMTRAK® (tebentafusp) for the treatment of unresectable or metastatic uveal melanoma
Mar 03, 2022 7:00am EST Immunocore Reports Full Year 2021 Financial Results and Provides Business Update
Feb 25, 2022 2:00am EST Immunocore receives positive CHMP opinion for KIMMTRAK® (tebentafusp) for the treatment of unresectable or metastatic uveal melanoma
Jan 26, 2022 7:00am EST Immunocore announces FDA approval of KIMMTRAK® (tebentafusp-tebn) for the treatment of unresectable or metastatic uveal melanoma